NYU Langone’s Perlmutter Cancer Center Launches New GI cancer Center with Renowned Physician-Scientists
Table of Contents
Meta Description: NYU Langone’s Perlmutter Cancer Center establishes a cutting-edge GI Cancer Center under the leadership of Drs. maitra and Hidalgo, accelerating research and treatment.
NYU langone Health’s Perlmutter cancer Center has announced the launch of a new Gastrointestinal (GI) Cancer Center, spearheaded by acclaimed leaders Anirban Maitra, MD, and Manuel Hidalgo, MD. This initiative represents a notable step forward in the center’s commitment to becoming a global leader in GI cancer care, integrating robust research with advanced clinical practise to expedite the growth of novel treatments.
Pioneering Leadership in GI Cancer Research
Dr. Maitra, a world-renowned physician-scientist, brings extensive expertise in pancreatic cancer research, encompassing early detection, biomarker development, and innovative strategies for intercepting cancer progression. His work has profoundly influenced the field, and at NYU Langone, he will collaborate with the Department of Pathology to establish programs focused on spatial biology, molecular diagnostics, and tissue-based analytics.Dr. maitra will serve as co-director of the GI Cancer Center and associate director of translational research, driving the translation of laboratory discoveries into clinical applications across a range of diseases.
“We are positioned well at Perlmutter Cancer Center to create a truly world-class GI Cancer Center,” Dr. Maitra stated-a testament to the institution’s commitment to excellence.
Advancing Drug Development and Personalized Treatment
Dr. Hidalgo is a highly respected translational researcher and clinical oncologist with a distinguished record in anticancer drug development. He has overseen the early clinical development of over 50 novel agents that have redefined the standard of care for patients battling advanced cancers. A pioneer in utilizing patient-derived xenografts – a technique employing a patient’s tumor sample to personalize treatment strategies – Dr. hidalgo’s work effectively bridges the gap between laboratory findings and clinical implementation. At Perlmutter Cancer Center, he will concentrate on building a strong infrastructure for therapeutic development, investigator-initiated trials, and studies guided by biomarkers.
“I am honored to join Perlmutter Cancer Center and help lead the development of this ambitious GI Cancer Center alongside Dr. Maitra,” Dr. Hidalgo said-underscoring the collaborative spirit of the endeavor.
A Collaborative Approach to Cancer Care
Drs.Maitra and Hidalgo previously collaborated to establish a prosperous pancreatic cancer center earlier in their careers. Their reunion at NYU Langone is expected to foster a collaborative habitat, uniting the GI Cancer Center with the institution’s multidisciplinary teams of surgical, radiation, and medical oncologists, gastroenterologists, and researchers. This synergy aims to accelerate the conversion of scientific breakthroughs into practical treatments for patients.
John P. Leonard, MD, chief of the Division of Hematology and Medical Oncology at NYU Grossman School of Medicine and director of the Center for Blood cancers at Perlmutter Cancer Center, expressed excitement about the potential of this new center to transform GI cancer care.
The launch of the GI Cancer Center underscores Perlmutter Cancer Center’s dedication to innovation and its commitment to providing patients with access to the most advanced and effective cancer treatments available.
